High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment

High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment

High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.

Study Assessing Dalantercept Plus Axitinib for Advanced Clear Cell RCC

Study Assessing Dalantercept Plus Axitinib for Advanced Clear Cell RCC

Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).

Various Targeted Therapies in RCC Coming Down the Pipeline

Various Targeted Therapies in RCC Coming Down the Pipeline

There are various emerging targeted therapies in renal cell carcinoma (RCC), including cabozantinib, dalantercept plus axitinib.

Study Supports Standard Sequence of Sunitinib Followed by Everolimus in mRCC

Study Supports Standard Sequence of Sunitinib Followed by Everolimus in mRCC

Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.

Axitinib Treatment May Result in Higher Drug Costs Than Everolimus for Advanced RCC

Axitinib Treatment May Result in Higher Drug Costs Than Everolimus for Advanced RCC

Axitinib treatment may result in higher drug costs compared with everolimus.

Adding TRC105 to Axitinib May Improve PFS for Clear Cell RCC

Adding TRC105 to Axitinib May Improve PFS for Clear Cell RCC

A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.

Alternative Axitinib Dose Escalation Schema May Improve Tolerability in mRCC

Alternative Axitinib Dose Escalation Schema May Improve Tolerability in mRCC

Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).

Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/Sorafenib

Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/Sorafenib

Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).

Almost Half of All Patients With mRCC Defer Frontline Systemic Therapy

Almost Half of All Patients With mRCC Defer Frontline Systemic Therapy

A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.

Management of Immune-Related Adverse Events

Management of Immune-Related Adverse Events

Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.

Should Checkpoint Inhibitors Precede IL-2 as Initial Therapy for mRCC

Should Checkpoint Inhibitors Precede IL-2 as Initial Therapy for mRCC

Differing opinions on initial therapy for patients with metastatic renal cell carcinoma (mRCC).

First-line Sunitinib, Pazopanib Have Similar Efficacy for mRCC in Population-based Setting

First-line Sunitinib, Pazopanib Have Similar Efficacy for mRCC in Population-based Setting

In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).

Nivolumab Continuation after Disease Progression May Be Safe, Effective for mRCC

Nivolumab Continuation after Disease Progression May Be Safe, Effective for mRCC

Patients with clear cell renal cell carcinoma who experience RECIST-defined disease progression may be able to safely continue nivolumab treatment.

Clinical Benefit, Patient Characteristics Common Reasons for Initial mRCC Systemic Therapy

Clinical Benefit, Patient Characteristics Common Reasons for Initial mRCC Systemic Therapy

Clinical benefit and patient characteristics were common reasons for initial systemic therapy for patients with metastatic renal cell carcinoma (mRCC).

Third-line Targeted Therapy Should Be Offered to Eligible Patients with mRCC

Third-line Targeted Therapy Should Be Offered to Eligible Patients with mRCC

Third-line targeted therapy has demonstrated activity and should be offered to clinically eligible patients with metastatic renal cell carcinoma (mRCC).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs